Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05498155 · ClinicalTrials.gov registry record · Phase 2

Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by AstraZeneca.

Active
Registry status
Phase 2
Development phase
50
Enrollment target
20
Study locations

NCT05498155 is a Phase 2 study of Breast Cancer that is active but no longer recruiting, run by AstraZeneca. The registered enrollment target is 50 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05498155, a Phase 2 study of Breast Cancer, is active but no longer recruiting, sponsored by AstraZeneca.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
20
Study locations

Study Summary

This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly \[adenosine diphosphate-ribose\] polymerase) inhibitor. PARP inhibitors can destroy cancer cells that are not good at repairing DNA damage. Olaparib is also approved by US Food and Drug Administration (FDA), European Medicines Agency (EMA) and in other countries for treating women with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer. Durvalumab is a type of anticancer drug called immunotherapy that targets cancer cells by blocking the signal that prevents the immune system from seeing the cancer cell. Your immune system can then attack and kill the cancer cells. Durvalumab is approved by the FDA and the EMA for the treatment of patients with locally advanced non-small cell lung cancer after receiving chemoradiation therapy and extensive-stage small cell lung cancer in combination with chemotherapy. Some parts of this study are experimental, which means that durvalumab and the combination of olaparib and durvalumab are still in the development stage for the treatment of breast cancer, and they are not approved for treatment of breast cancer, except for use in research studies like this.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Neoadjuvant Olaparib monotherapy group
  • COMBINATION_PRODUCT Neoadjuvant combination therapy with olaparib plus durvalumab

Study Locations (20)

Other

  • Research Site - Melbourne
  • Research Site - Rankweil
  • Research Site - Salzburg
  • Research Site - Brussels
  • Research Site - Liège
  • Research Site - Augsburg, by
  • Research Site - Cologne
  • Research Site - Essen
  • Research Site - Hamburg
  • Research Site - Hanover
  • Research Site - Heidelberg
  • Research Site - München
  • Research Site - Jerusalem
  • Research Site - Kfar Saba
  • Research Site - Ramat Gan

Colorado

  • Research Site - Greeley
  • Research Site - Loveland

Massachusetts

  • Research Site - Boston

Oregon

  • Research Site - Portland

Pennsylvania

  • Research Site - Philadelphia

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-11-07
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05498155

The ClinicalTrials.gov registry entry for NCT05498155 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Neoadjuvant Olaparib monotherapy group is the first listed.

NCT05498155 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Other, Colorado, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05498155 about?

NCT05498155 is a clinical study titled "Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer". This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems. Olaparib is a type of drug called a PARP (poly \[adenosine diphosphate-ribose\] polymerase) inhibitor. PARP inhi...

What is the current status of trial NCT05498155?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2022-11-07. Estimated completion is 2026-12-31.

What conditions does trial NCT05498155 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT05498155?

The interventions under investigation include: Neoadjuvant Olaparib monotherapy group (DRUG), Neoadjuvant combination therapy with olaparib plus durvalumab (COMBINATION_PRODUCT).

Who is sponsoring clinical trial NCT05498155?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05498155 being conducted?

This trial has 20 study locations across Colorado, Massachusetts, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.